A drug calmed a harmful CAR T reaction in mice
Original title: Targeting CCR1/CCR2 attenuates cytokine release syndrome while preserving CAR T-cell antitumor activity.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
The drug was only tested in mice.
The short version
A drug eased a dangerous reaction to CAR T therapy in mice, without weakening it.
What was studied. Scientists gave CAR T-cell therapy to mice carrying human tumors and tracked the immune reaction. They also looked at cell data from people with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary who had CAR T therapy.
What they found. After CAR T cells, the mice had a strong body-wide immune reaction. Immune cells called macrophages built up, and two of their signals, CCR1 and CCR2, became very active. A drug that blocked those two signals calmed the reaction without weakening the CAR T cells.
What this means, and what it doesn't
What it could mean: CAR T therapy can set off a dangerous reaction called cytokine release syndrome. This work points to one possible way to calm that reaction. Whether it helps patients is still unknown.
What it doesn't mean: This was tested in mice, not in people. The patient part was only a look at cell data, not a treatment test. This is early lab and animal work, far from everyday care. It is not a cure, and it will not change your treatment now. Human trials would have to come first.
Source: PubMed, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.